8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2015

Wound Management Technologies, Inc.

(Exact name of registrant as specified in its charter)

Texas	000-11808	59-2219994
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

16633 Dallas Parkway, Suite 250 Addison, Texas	75001
(Address of principal executive offices)	(zip code)

Registrant’s telephone number, including area code: (972) 218-0935

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

       

Item 7.01 Regulation FD Disclosure

The information provided pursuant to this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by Wound Management Technologies, Inc. pursuant to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document. The information provided pursuant to this Item 7.01 shall instead be deemed “furnished.”

On April 20, 2015, Wound Management Technologies, Inc. (the "Company") announced that it will conduct an earnings conference call on Wednesday, April 22, 2015 at 3:00 p.m. CST during which the Company will discuss first quarter 2015 results and provide an update on recent activities. The press release announcing the conference call information is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit 99.1 Wound Management Technologies, Inc. press release announcing conference call on first quarter 2015 results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Wound Management Technologies, Inc.
Date: April 20, 2015	By:	/s/ Darren Stine
		Darren Stine
		Chief Financial Officer

EX-99.1

Exhibit 99.1

Wound Management Technologies, Inc. Schedules First Quarter 2015 Earnings call for Wednesday, April 22, 2015

Addison, TEXAS, April 20, 2015 – Wound Management Technologies, Inc. (OTC QB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced it will conduct a quarterly earnings call on Wednesday, April 22, 2015 at 3:00 p.m. CST.  Robert Lutz, Jr., CEO, will discuss first quarter 2015 results and provide and update on recent activities.  A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may join the call by dialing 1-712-775-7031 passcode 604070847# shortly before 3:00 p.m. CST.

About Wound Management Technologies

Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market.  Wound Management’s primary focus is the distribution of its Wound Care Innovations subsidiary’s unique, patented collagen product line, CellerateRX® which is FDA-cleared for all wound types except 3rd degree burns. The wound care product line is reimbursable under Medicare Part B and the surgical products are reimbursable as part of procedural billing.  Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development.  For more information visit www.wmgtech.com.

To download Wound Management Technologies’ investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit http://bit.ly/1zhNwnO to download on your iPhone and iPad or http://bit.ly/149PgWc for your Android mobile device.

Information about Forward-Looking Statements

The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

Investor Contacts:

Robert Lutz Jr. / Darren Stine

972.218.0935

rlutz@wmgtech.com / dstine@wmgtech.com